Enterprise file synchronization and sharing

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, November 8, 2023

HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shares of its common stock at a public offering price of $27.00 per share.

Key Points: 
  • HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shares of its common stock at a public offering price of $27.00 per share.
  • In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,113,750 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • Jefferies, Leerink Partners, Guggenheim Securities and Cantor are acting as the joint book-running managers for the offering.
  • LifeSci Capital and H.C. Wainwright & Co. are acting as co-lead managers for the offering.

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, November 7, 2023

HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

Key Points: 
  • HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.
  • Celldex expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
  • All of the shares of common stock are being offered by the Company.
  • Jefferies and Leerink Partners are acting as the joint book-running managers for the proposed offering.

Atlanta Braves Holdings, Inc. Announces Pricing of Secondary Public Offering of Common Stock

Retrieved on: 
Monday, November 6, 2023

Atlanta Braves Holdings, Inc. (Nasdaq: BATRA, BATRK) (“Atlanta Braves Holdings”) today announced the pricing of the previously announced secondary public offering of 1,811,066 shares of its Series C common stock (the “Shares”).

Key Points: 
  • Atlanta Braves Holdings, Inc. (Nasdaq: BATRA, BATRK) (“Atlanta Braves Holdings”) today announced the pricing of the previously announced secondary public offering of 1,811,066 shares of its Series C common stock (the “Shares”).
  • The offering is expected to close on or about November 9, 2023, subject to customary closing conditions.
  • Atlanta Braves Holdings will not receive any of the proceeds from the sale of the Shares by the Selling Stockholder in the offering.
  • A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on November 6, 2023.

OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction

Retrieved on: 
Tuesday, October 31, 2023

The reduction of payables is considered by the Company to be a major endorsement by its creditors of its current strategy and constitutes a material reduction of OKYO’s payables.

Key Points: 
  • The reduction of payables is considered by the Company to be a major endorsement by its creditors of its current strategy and constitutes a material reduction of OKYO’s payables.
  • The gross cash proceeds to OKYO from the registered direct offering, before deducting offering expenses payable by OKYO, are expected to be $1.64M, together with a reduction of $4.20M of payables.
  • The offering is expected to close on or about November 1 2023, subject to the satisfaction of customary closing conditions.
  • OKYO intends to use the net proceeds from the offering primarily for clinical development of the Company’s product candidates, general corporate purposes and working capital.

Draganfly Announces Closing of US$3.5 Million Underwritten Offering

Retrieved on: 
Monday, October 30, 2023

Los Angeles, CA., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, is pleased to announce that it has closed its previously announced underwritten offering for gross proceeds of approximately US$3.5 million (the “Offering”), before deducting underwriting discounts and offering expenses.

Key Points: 
  • Los Angeles, CA., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, is pleased to announce that it has closed its previously announced underwritten offering for gross proceeds of approximately US$3.5 million (the “Offering”), before deducting underwriting discounts and offering expenses.
  • Each Unit is comprised of one common share (a “Common Share”) and one common share purchase warrant (a “Warrant”).
  • Each Pre-Funded Unit is comprised of one pre-funded common share purchase warrant ‎‎(a “Pre-Funded Warrant”) and one Warrant.
  • The Offering was made pursuant to an effective shelf registration statement on Form F-10, as amended, (File No.

Atlanta Braves Holdings, Inc. Announces Launch of Secondary Public Offering of Common Stock

Retrieved on: 
Monday, November 6, 2023

Atlanta Braves Holdings, Inc. (Nasdaq: BATRA, BATRK) (“Atlanta Braves Holdings”) today announced a proposed secondary public offering of 1,811,066 shares of its Series C common stock (the “Shares”) currently held by Liberty Media Corporation (“Liberty Media”).

Key Points: 
  • Atlanta Braves Holdings, Inc. (Nasdaq: BATRA, BATRK) (“Atlanta Braves Holdings”) today announced a proposed secondary public offering of 1,811,066 shares of its Series C common stock (the “Shares”) currently held by Liberty Media Corporation (“Liberty Media”).
  • The Selling Stockholder then expects to sell the Shares to the underwriter in the offering.
  • Atlanta Braves Holdings is not selling any shares of its common stock and will not receive any of the proceeds from the sale of the Shares by the Selling Stockholder in the offering.
  • The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

TransCode Therapeutics Announces Public Offering of Common Stock

Retrieved on: 
Thursday, October 26, 2023

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an underwritten public offering of shares of its common stock.

Key Points: 
  • BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an underwritten public offering of shares of its common stock.
  • In addition, the Company expects to grant the underwriters a 45-day option to purchase additional shares of its common stock in an amount equal to 15% of the shares offered in the public offering.
  • The offering of common stock is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • All shares to be sold in the proposed offering of common stock will be offered by the Company.

Draganfly Announces Pricing of US$3.5 Million Underwritten Offering

Retrieved on: 
Thursday, October 26, 2023

Each common share (or pre-funded warrant to purchase one common share) was sold together with one warrant at a combined public offering price of US$0.55, for gross proceeds of approximately US$3.5 million (the “Offering”), before deducting underwriting discounts and offering expenses.

Key Points: 
  • Each common share (or pre-funded warrant to purchase one common share) was sold together with one warrant at a combined public offering price of US$0.55, for gross proceeds of approximately US$3.5 million (the “Offering”), before deducting underwriting discounts and offering expenses.
  • Maxim Group LLC is acting as sole book-running manager for the Offering.
  • The Offering is expected to close on or about October 30, 2023, subject to the satisfaction of customary closing conditions.
  • The Offering is being made pursuant to an effective shelf registration statement on Form F-10, as amended, (File No.

AppTech Payments Corp. Announces Pricing of $3.5 Million Registered Direct Offering

Retrieved on: 
Tuesday, October 24, 2023

The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $2.10.

Key Points: 
  • The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $2.10.
  • Titan Partners Group, a division of American Capital Partners, is acting as sole placement agent for the offering.
  • The offering is expected to close on or about October 26, 2023, subject to the satisfaction of customary closing conditions.
  • The shares of common stock and warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No.

ATEC Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, October 24, 2023

Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that it has commenced a proposed underwritten public offering of $150 million of shares of its common stock.

Key Points: 
  • Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that it has commenced a proposed underwritten public offering of $150 million of shares of its common stock.
  • In connection with the proposed offering, ATEC intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock sold in the offering.
  • All of the shares in the offering are to be sold by ATEC.
  • The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No.